Malaga Cove Capital LLC Buys 615 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Malaga Cove Capital LLC grew its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,367 shares of the medical research company’s stock after purchasing an additional 615 shares during the quarter. Malaga Cove Capital LLC’s holdings in Charles River Laboratories International were worth $796,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Asset Management One Co. Ltd. grew its holdings in Charles River Laboratories International by 7.7% in the 3rd quarter. Asset Management One Co. Ltd. now owns 20,573 shares of the medical research company’s stock valued at $4,032,000 after buying an additional 1,474 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in Charles River Laboratories International by 9.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 30,720 shares of the medical research company’s stock valued at $6,021,000 after purchasing an additional 2,643 shares during the last quarter. Xponance Inc. boosted its holdings in Charles River Laboratories International by 4.7% in the 3rd quarter. Xponance Inc. now owns 7,389 shares of the medical research company’s stock valued at $1,448,000 after purchasing an additional 335 shares during the period. Raymond James & Associates grew its position in Charles River Laboratories International by 2.4% in the 3rd quarter. Raymond James & Associates now owns 252,176 shares of the medical research company’s stock worth $49,421,000 after purchasing an additional 6,013 shares during the last quarter. Finally, Stratos Wealth Partners LTD. increased its holdings in shares of Charles River Laboratories International by 24.5% during the 3rd quarter. Stratos Wealth Partners LTD. now owns 2,505 shares of the medical research company’s stock worth $491,000 after purchasing an additional 493 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares of the company’s stock, valued at $5,685,431.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, VP William D. Barbo sold 4,050 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the sale, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last three months. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Price Performance

NYSE CRL traded up $3.58 during trading hours on Friday, reaching $233.47. 466,193 shares of the company’s stock were exchanged, compared to its average volume of 482,082. The firm has a fifty day moving average of $252.23 and a 200-day moving average of $224.20. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00. The stock has a market cap of $12.03 billion, a PE ratio of 25.35, a price-to-earnings-growth ratio of 1.83 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. During the same period last year, the company posted $2.98 earnings per share. The firm’s quarterly revenue was down 7.9% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research reports. Citigroup increased their target price on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Robert W. Baird lifted their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Guggenheim cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. UBS Group upped their target price on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Evercore ISI raised their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).